WSJ: Big Brokerage firms in the U.S. move to shield investors from the island’s bonds.
FT: Taper delay could be good news for stocks and bonds.
Learn Bonds: An introduction to income investing.
FT: Investors pour money into high yield.
Morningstar: The bond market after Lehman vs. the state of the bond market now.
Top 5 Gas Utility Stocks To Invest In 2015: American Midstream Partners LP (AMID)
American Midstream Partners, LP, incorporated on August 20, 2009, owns, operates, develops and acquires a portfolio of natural gas midstream energy assets. The Company is engaged in the business of gathering, treating, processing and transporting natural gas through its ownership and operation of 10 gathering systems, four processing facilities and a 50% non-operating interest in a fifth plant, two interstate pipelines and four intrastate pipelines. Its assets are located in Alabama, Louisiana, Mississippi, Tennessee and Texas, provide infrastructure, which links producers and suppliers of natural gas to diverse natural gas markets, including interstate and intrastate pipelines, as well as utility, industrial and other commercial customers. In December 2013, American Midstream Partners, LP acquired Blackwater Midstream Holdings, LLC from an affiliate of ArcLight Capital Partners, LLC. In February 2014, Penn Virginia Corporation sold all of its Eagle Ford Shale natural gas midstream assets to the Company.
The Company operates in two segments: Gathering and Processing, and Transmission. In its gathering and processing segment, it receives fee-based and fixed-margin compensation for gathering, transporting and treating natural gas. Where it provide processing services at the plants that it owns, or obtain processing services for its own account under its elective processing arrangements. During the year ended December 31, 2012, it owned four processing facilities that produced an average of approximately 49.9 million gallons of liquid per day of gross natural gas liquids (NGLs). In addition, under its elective processing arrangements, it contracts for processing capacity at a third-party plant where it has the option to process natural gas that it purchases. During 2012, under these arrangements, it sold an average of approximately 27.9 million gallons of liquid per day of net equity NGL volumes. It also receives fee-based and fixed -margin compensation in its transmission segment related to ! capacity reservation charges under its firm transportation contracts and the transportation of natural gas.
Gathering and Processing
The Company’s gathering and processing segment provides wellhead to market services for natural gas to producers of natural gas and oil, which include transporting raw natural gas from various receipt points through gathering systems, treating the raw natural gas, processing raw natural gas to separate the NGLs and selling or delivering pipeline quality natural gas, as well as NGLs to various markets and pipeline systems. It gathers and processes natural gas pursuant to arrangements, including fee-based arrangements, fixed-margin arrangements and percent-of-proceeds arrangements.
The Company competes with Tennessee Gas Pipeline (TGP), Gulf South and ANR.
The Company’s transmission segment transports and delivers natural gas from producing wells, receipt po ints or pipeline interconnects for shippers and other customers, which include local distribution companies (LDCs), utilities and industrial, commercial and power generation customers. Results of operations from its transmission segment are determined by capacity reservation fees from firm transportation contracts and the volumes of natural gas transported on the interstate and intrastate pipelines it owns. Its transportation arrangements include firm transportation arrangements, interruptible transportation and fixed-margin contracts. Its Midla and AlaTenn systems are interstate natural gas pipelines. Its Bamagas system is a Hinshaw intrastate natural gas pipeline, which travels west to east from an interconnection point with TGP in Colbert County, Alabama to two power plants owned by Calpine Corporation (Calpine), in Morgan County, Alabama. The Bamagas system consists of 52 miles of high pressure, 30-inch pipeline with a design capacity of approximately 450 million cubic f eet per day.
The AlaTenn system is an intersta! te natura! l gas pipeline that interconnects with TGP and travels west to east delivering natural gas to industrial customers in northwestern Alabama, as well as the city gates of Decatur and Huntsville, Alabama. Its AlaTenn system has a design capacity of approximately 200 million gallons of liquid per day and is consisted of approximately 295 miles of pipeline with diameters ranging from three to 16 inches and includes two compressor stations with combined capacity of 3,665 horsepower. The AlaTenn system is connected to four receipt and 61 delivery points, including the Tetco Pipeline system, an interstate pipeline owned by Duke Energy Corporation, and the Columbia Gulf Pipeline system, an interstate pipeline owned by NiSource Gas Transmission and Storage.
The Company’s Midla system is an interstate natural gas pipeline with approximately 370 miles of pipeline linking the Monroe Natural Gas Field in Northern Louisiana and interconnections with the Transco Pipeline sys tem and Gulf South Pipeline system to customers near Baton Rouge, Louisiana. Its Midla system also has interconnects to Centerpoint, TGP and Sonat along a high-pressure lateral at the north end of the system, called the T-32 lateral. Its Midla system is located near the Perryville Hub, which is a hub for natural gas produced in the Louisiana and broader Gulf Coast region, including natural gas from the Haynesville shale, Barnett shale, Fayetteville shale, Woodford shale and Deep Bossier formations of Northern Louisiana, Central Texas, Northern Arkansas, Eastern Oklahoma and East Texas, respectively. The Midla system is connected to nine receipt and 19 delivery points. The northern portion of the system, including the T-32 lateral, consists of approximately four miles of high pressure, 12-inch diameter pipeline. Natural gas on the northern end of the Midla system is delivered to two power plants operated by Entergy by way of the T-32 lateral and the CLECO Sterlington plant by way of the Sterlington lateral.
The Company’! s mainlin! e of the system has a design capacity of approximately 198 million cubic feet per day and consists of approximately 172 miles of low pressure, 22-inch diameter pipeline with laterals ranging in diameter from two to 16 inches. During 2012, average throughput on the Midla mainline was approximately 72.7 million cubic feet per day. The southern portion of the system, including interconnections with the MLGT system and other associated laterals, consists of approximately two miles of high and low pressure, 12-inch diameter pipeline. This section of the system primarily serves industrial and LDC customers in the Baton Rouge market. In addition, this section includes two small offshore gathering lines, the T-33 lateral in Grand Bay and the T-51 lateral in Eugene Island 28, each of which are approximately five miles in length. Natural gas delivered on the southern end of the system is sold under both firm and interruptible transportation contracts with average remaining terms of tw o years.
The MLGT system is an intrastate transmission system that sources natural gas from interconnects with the FGT Pipeline system, an interstate pipeline owned by Florida Gas Transmission Company, the Tetco Pipeline system, the Transco Pipeline system and its Midla system to a Baton Rouge, Louisiana refinery owned and operated by ExxonMobil and five other industrial customers. Its million cubic feet per day system has a design capacity of approximately 170 million cubic feet per day and is consisted of approximately 54 miles of pipeline with diameters ranging from three to 14 inches. The MLGT system is connected to seven receipt and 16 delivery points. During 2010, average throughput on the MLGT system was approximately 50.5 million cubic feet per day.
The Company’s other transmission systems include the Chalmette system, located in St. Bernard Parish, Louisiana, and the Trigas system, located in three counties in northwestern Alabama. The ap proximate design capacities for the Chalmette and Trigas sys! tems are ! 125 million cubic feet per day and 60 million cubic feet per day, respectively. During 2012, the approximate average throughput for these systems was 9.8 MMcf/d and 10.6 MMcf/d. It also owns a range of interconnects and small laterals that are referred to as the SIGCO assets.
The Company competes with Southern Natural Gas Company and Louisiana Intrastate Gas.
- [By Robert Rapier and Igor Greenwald]
Some MLPs have experienced huge capital appreciation. Three–Icahn Enterprises (Nasdaq: IEP), Hi-Crush Partners (NYSE: HCLP), and The Blackstone Group (NYSE: BX)–gained over 100 percent in 2013. A fourth, American Midstream Partners (NYSE: AMID) gained 96 percent for the year.
- [By Monica Gerson]
American Midstream Partners LP (NYSE: AMID) is estimated to post a Q4 loss at $0.30 per share on revenue of $89.74 million.
Hill International (NYSE: HIL) is expected to post its Q4 earnings at $0.01 per share on revenue of $134.74 million.
Top 5 Gas Utility Stocks To Invest In 2015: AspenBio Pharma Inc.(APPY)
AspenBio Pharma, Inc. operates as an emerging biomedical company focused on obtaining the United States FDA clearance for its lead product, AppyScore. Its research and development activities primarily focus on a human appendicitis blood-based test. The company?s lead product candidate, AppyScore, is a blood-based diagnostic test to help physicians manage patients who enter emergency rooms complaining of abdominal pain and suspected of having acute appendicitis. It is also developing animal healthcare products focusing on reproduction. The company was formerly known as AspenBio, Inc. and changed its name to AspenBio Pharma, Inc. on September 26, 2005. AspenBio Pharma, Inc. was founded in 2000 and is based in Castle Rock, Colorado.
- [By Wallace Witkowski]
Venaxis Inc. (APPY) shares fell 12% to $2.38 on light volume after the medical diagnostics company said it planned to launch an secondary offering of an unspecified number of shares.
- [By Monica Gerson]
Venaxis (NASDAQ: APPY) soared 22.83% to $3.33 in the pre-market trading on positive top-line results from pivotal study of APPY1 test.
Plug Power (NASDAQ: PLUG) shares gained 11.18% to $7.56 in the pre-market after the company reported fourth-quarter results. Plug Power posted a quarterly loss of $0.08 per share, versus the estimated loss of $0.08 per share.
- [By Bryan Murphy]
If you’re reading this, then odds are you know that Venaxis Inc. (NASDAQ:APPY) shares are up a solid 10% today, while the market as a whole is in the red. What you may not know about APPY, however, is that with today’s strength, the stock has worked its way past a big hurdle and put itself into a situation where more upside is very likely.
- [By Lee Jackson]
Vernaxis Inc. (NASDAQ: APPY) is an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE MarkedAPPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis. They have moved ahead with their pivotal trial enrollment, and the analyst at Canaccord Genuity rates the company as a stock to buy. Its price target for the stock is a whopping $7, the high target for the stock. A move to that level would represent a 250% move for shareholders. The consensus target is at $5.25. Vernaxis closed Friday at $1.97.
Top 5 Gas Utility Stocks To Invest In 2015: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Preventio n of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company’s Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company’s second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 br east cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical tri als. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
- [By Michael Douglass and David Williamson]
Galena Biopharma (NASDAQ: GALE ) announced this morning that it has licensed the rights to sell Zuplenz for $5 million in stock and cash, in addition to royalties, milestones, and an upfront payment.
- [By James E. Brumley]
The last two weeks have been absolutely fantastic ones for Galena Biopharma Inc. (NASDAQ:GALE). Shares have soared from $2.37 to the current price of $3.32 – a 40% pop – rewarding investors who had been patiently waiting through late October for the runup to take hold. Congratulations if that’s you. But, if that was you, then now might be a great time to take the money and run with the trade, as GALE looks poised to make a sizeable pullback. More on that in a moment.
- [By James E. Brumley]
It may look like little more than a choppy mess with just a quick glance at Galena Biopharma Inc. (NASDAQ:GALE). But, the more you study the chart – and the company – the more you realize there’s enough long-term potential from the company’s pipeline to keep spurring GALE in a generally-upward direction. In fact, the bulls look like they’re on the verge of taking Galena Biopharma out of second gear and putting it into third. As such, it may not be a bad bet at this point.
Top 5 Gas Utility Stocks To Invest In 2015: Skilled Healthcare Group Inc.(SKH)
Skilled Healthcare Group, Inc., through its subsidiaries, operates skilled nursing facilities, assisted living facilities, hospices, home health providers, and a rehabilitation therapy business. Its skilled nursing facilities provide specialty care, such as chemotherapy, enteral/parenteral nutrition, tracheotomy care, and ventilator care, as well as offers various services, including room and board, special nutritional programs, social services, recreational activities, and related healthcare and other services. These skilled nursing facilities include Express Recovery, a unit that provides skilled nursing care and rehabilitation therapy for patients recovering from conditions, such as joint replacement surgery, and cardiac and respiratory ailments. The company?s assisted living facilities provide residential accommodations, activities, meals, security, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support , but not the level of nursing care provided in a skilled nursing facility. Skilled Healthcare Group also offers ancillary services, such as physical, occupational, and speech therapy, as well as rehabilitation therapy service to third-party skilled nursing operators. In addition, the company offers hospice services comprising palliative and clinical care, education, and counseling with a focus on the physical, spiritual, and psychosocial needs of terminally ill individuals and their families. As of December 31, 2010, it owned or leased 78 skilled nursing facilities and 22 assisted living facilities, together comprising 10,830 licensed beds in California, Texas, Iowa, Kansas, Missouri, Nevada, and New Mexico. The company has a joint venture with APS?Summit Care Pharmacy, LLC that operates a pharmacy in Austin, Texas. Skilled Healthcare Group, Inc. is based in Foothill Ranch, California.
- [By Rich Smith]
Foothill Ranch, Calif.-based Skilled Healthcare (NYSE: SKH ) needs a new CEO.
On Monday, the assisted living facilities operator announced that Chief Executive Officer Boyd Hendrickson plans to retire from the company at the end of this year. A search for a replacement is now under way.
Top 5 Gas Utility Stocks To Invest In 2015: NuVasive Inc.(NUVA)
NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedures for the spine. The company?s products focus on applications for spine fusion surgery. It offers products primarily for the thoracolumbar spine and cervical spine. The company?s principal products include a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as cervical, biologics, and motion preservation products. Its MAS platform combines four categories of product offerings, including NVM5 and NVJJB, its proprietary software-driven nerve monitoring systems; MaXcess system that provides access to the spine with minimal soft tissue disruption; specialized implants that are used for interbody disc height restoration for fusion and stabilization of the spine, as well as biologic products comprising FormaGraft, a collagen-based synthetic bone substitute and Osteocel Plus, an allograft cellular ma t rix. Its biologic products also comprise AttraX, a synthetic bone graft material; and Triad, an allograft cellular matrix containing viable mesenchymal stem cells. In addition, the company offers a range of bone allograft in patented saline packaging; disposables and spine implants under the CoRoent brand name; and fixation devices, such as rods, plates, and screws. Further, it provides intra-operative monitoring services for insight into the nervous system during spine and other surgeries. Additionally, the company is developing total disc replacement devices for lateral lumbar spine and cervical spine applications. NuVasive, Inc. sells its products through directly-employed sales shareowners, independent sales agents, and distributors to surgeons and hospitals in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
- [By Bryan Murphy]
It may not be as big as NuVasive, Inc. (NASDAQ:NUVA), and it might not be as sexy as MiMedx Group Inc. (NASDAQ:MDXG). But, Bacterin International Holdings Inc. (NYSEMKT:BONE) offers something to investors that MDXG and NUVA don’t – can’t – right now… a distinct opportunity for a lot of upside in a short amount of time.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Wednesday’s session are Bank of America Corp.(BAC), Chelsea Therapeutics International Ltd.(CHTP) and NuVasive Inc.(NUVA)